Taking a quick look at some possible support and resistance levels on shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), we can see that the 52-week high is currently 183.18, and the 52-week low is currently 115.94. When shares are trading close to the 52-week high or 52-week low, investors may be watching for a move through either level. Checking in on recent action, we note that the stock has been trading near the $139.17 level. Investors may also want to keep an eye on historical price activity. During the past 12 weeks, the stock has moved 11.05%. Looking further back to the start of the calendar year, we can see that shares have moved 12.27%. Over the past 4 weeks, shares have seen a change of -0.45%. Over the last 5 trading days, the stock has moved 7.41%. Investors will be monitoring stock activity over the next few sessions to try and decipher which way the momentum is leaning.
When conducting stock research, some investors will choose to start from the top-down while others may choose to begin from the bottom-up. Starting from the top-down typically includes studying the overall economy, industries, and multiple markets. Stocks tend to perform differently at certain points in economic cycles. Figuring out where the economy is can help find the sectors that will outperform. Once specific sectors are identified, investors might be able to then select certain stocks within those sectors. Investors who start with from the bottom-up may start by analyzing individual stocks first. This may include looking for stocks that are undervalued in relation to the perceived value of the company. Many investors will use a combination of both styles when undertaking detailed stock research.
Analysts have set a target price on shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ). The current consensus price target is $177.56. Wall Street analysts often provide price target projections on stocks that they cover. Price target projections can be created using a wide variety of methods. Many investors will closely track stock target prices, especially when analysts make updates. A thorough research report will generally offer detailed reasoning for a certain target projection. Some investors may watch sell-side targets very closely and use the information to help with their own stock research.
Just-released report names Cannabis Stock of the Year for 2019! Their last pick has seen a +1,200% return since he released it!
This stock has all of the makings of the next great cannabis stock – early-mover advantage, international exposure and influential partnerships, plus it has a product that is unlike anything else on the market…
Sell-side analysts have the capability of providing stock ratings for companies that they cover. According to analysts polled by Zacks Research, the current average broker rating on shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is 1.44. This average rating includes analysts who have offered Sell, Buy and Hold ratings on the stock. This rating falls on a numeric scale from 1 to 5. A score of 1 would indicate a Buy recommendation, and a score of 5 would represent a Sell recommendation. Out of all the analysts offering ratings, 13 have pegged the stock a Strong Buy or Buy, based on data provided by Zacks Research.
Tracking the current quarter consensus EPS estimate for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), we have noted that the number is currently 3.61. This estimate is using 10 contributing analysts polled by Zacks Research. For the last quarter, the company posted a quarterly EPS of 3.67. Sell-side Wall Street analysts study companies and provide their opinions of where the stock might be going in the future. A lot of weight is given to analyst estimates, and earnings beats or misses revolve around these predictions. Sometimes these estimates are very close to the actual, and other times they are not. When a company announces actual earnings results, a large surprise factor can result in increased volatility. If a company beats estimates and posts a positive earnings surprise, the stock may see a near-term bump in price. On the flip side, a negative surprise may move the stock lower. Based on the unknown, many investors may choose to trade with caution around earnings releases.
Investors are often faced with difficult decisions when trading the equity market. Sometimes, the decision to sell a certain stock may be just as important as the decision to buy the stock in the first place. Individual investors may have done the research, had some good fortune, and are now dealing with a big winner in the portfolio. Even though a stock has had a big run, it may be time to unload and take some profits. Holding on to a winner too long can eat into profits that may have been better spent getting into another promising name. On the flip side, investors may have trouble letting go of an underperforming portfolio loser. The emotional attachment to a stock can cause the investor to hold onto a stock for way too long. Maybe the stock was thoroughly researched, but it just keeps going lower. Being able to cut the ties instead of waiting for a bounce back may be beneficial for portfolio health in the long run.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.